146 Results for "

stat5

" in MedChemExpress (MCE) Product Catalog:
Products (146)

146 Results for "stat5" in MCE Product Catalog:

105
Tofacitinib
Tofacitinib
0 Images
105 Publications Verification
Cat. No.: HY-40354
CAS No.: 477600-75-2
Synonyms: Tasocitinib; CP-690550
Target:  

JAK STAT NF-κB

Research Areas:  

Neurological Disease Metabolic Disease Inflammation/Immunology

Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [5] .
loading...
    loading...
View All Sizes
105
Tofacitinib citrate
Tofacitinib citrate
0 Images
105 Publications Verification
Cat. No.: HY-40354A
CAS No.: 540737-29-9
Synonyms: Tasocitinib citrate; CP-690550 citrate
Target:  

JAK STAT NF-κB

Research Areas:  

Neurological Disease Metabolic Disease Inflammation/Immunology

Tofacitinib citrate (Tasocitinib citrate) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib citrate blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib citrate can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [5] .
loading...
    loading...
View All Sizes
44
WP1066
WP1066
0 Images
44 Cited Publications
Cat. No.: HY-15312
CAS No.: 857064-38-1
Purity:  99.77%
Target:  

STAT JAK Apoptosis

Research Areas:  

Cancer

WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3. WP1066 can cross the blood-brain barrier[1][2][3][4].
loading...
    loading...
View All Sizes
34
STAT5-IN-1
STAT5-IN-1
0 Images
34 Cited Publications
Cat. No.: HY-101853
CAS No.: 285986-31-4
Purity:  98.35%
Target:  

STAT

Research Areas:  

Cancer

STAT5-IN-1 is a STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform.
loading...
    loading...
View All Sizes
20
SH-4-54
SH-4-54
0 Images
20 Cited Publications
Cat. No.: HY-16975
CAS No.: 1456632-40-8
Target:  

STAT

Research Areas:  

Neurological Disease Metabolic Disease Cancer

SH-4-54 is a CNS-penetrant STAT inhibitor that binds to STAT3 and STAT5 with KDs of 300, 464 nM, respectively .
loading...
    loading...
View All Sizes
20
Pacritinib
Pacritinib
0 Images
20 Cited Publications
Cat. No.: HY-16379
CAS No.: 937272-79-2
Synonyms: SB1518
Target:  

JAK FLT3 STAT ERK Akt Apoptosis

Pacritinib (SB1518) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis [5] .
loading...
    loading...
View All Sizes
20
Pacritinib citrate
Pacritinib citrate
0 Images
20 Cited Publications
Cat. No.: HY-16379B
CAS No.: 1228923-42-9
Synonyms: SB1518 citrate
Target:  

JAK FLT3 STAT ERK Akt Apoptosis

Research Areas:  

Metabolic Disease Cancer

Pacritinib citrate (SB1518 citrate) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib citrate inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib citrate normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib citrate can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis [5] .
loading...
    loading...
View All Sizes
12
Abrocitinib
Abrocitinib
0 Images
12 Cited Publications
Cat. No.: HY-107429
CAS No.: 1622902-68-4
Purity:  99.26%
Synonyms: PF-04965842
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .
loading...
    loading...
View All Sizes
8
AC-4-130
AC-4-130
0 Images
8 Cited Publications
Cat. No.: HY-124500
CAS No.: 1834571-82-2
Purity:  99.93%
Target:  

STAT Apoptosis

Research Areas:  

Cancer

AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .
loading...
    loading...
View All Sizes
8
XL019
XL019
0 Images
8 Cited Publications
Cat. No.: HY-13775
CAS No.: 945755-56-6
Purity:  99.65%
Target:  

JAK Apoptosis

Research Areas:  

Cancer

XL019?is a potent, orally active, and selective JAK2 inhibitor, with IC50s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .
loading...
    loading...
View All Sizes
8
ML115
ML115
0 Images
8 Cited Publications
Cat. No.: HY-111152
CAS No.: 912798-42-6
Purity:  99.89%
Target:  

STAT

Research Areas:  

Cancer

ML115, a molecular probe of the signal transducer, is a selective STAT3 agonist, with an EC50 of 2 nM. ML115 increases the expression of BCL3, a known STAT3-dependent oncogene. ML115 is inactive against the related STAT1, STAT5 and NF-κB anti-targets. ML115 counteracts the effects of Ginsenoside Rc (HY-N0042) on cell viability and inflammatory responses in LPS (HY-D1056)-stimulated H9c2 and RAW264.7 cells, while altering oxidative stress markers. ML115 can be used for the study of breast and prostate cancers .
loading...
    loading...
View All Sizes
8
Romaciclib monohydrochloride
Romaciclib monohydrochloride
0 Images
8 Cited Publications
Cat. No.: HY-111388A
CAS No.: 2443816-41-7
Purity:  99.29%
Synonyms: SEL120-34A monohydrochloride
Target:  

CDK

Research Areas:  

Cancer

SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726 . Has anti-tumor activity .
loading...
    loading...
View All Sizes
6
BD750
BD750
0 Images
6 Cited Publications
Cat. No.: HY-131140
CAS No.: 892686-59-8
Purity:  99.10%
Target:  

JAK STAT

Research Areas:  

Inflammation/Immunology Cancer

BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively .
loading...
    loading...
View All Sizes
6
AS2863619
AS2863619
0 Images
6 Cited Publications
Cat. No.: HY-126675A
CAS No.: 2241300-51-4
Purity:  99.94%
Target:  

STAT CDK Apoptosis TGF-beta/Smad

Research Areas:  

Inflammation/Immunology

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
View All Sizes
6
AS2863619 free base
AS2863619 free base
0 Images
6 Cited Publications
Cat. No.: HY-126675
CAS No.: 2241300-50-3
Purity:  99.68%
Target:  

CDK TGF-beta/Smad Apoptosis STAT

Research Areas:  

Inflammation/Immunology

AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
View All Sizes
5
Butyzamide
Butyzamide
0 Images
5 Cited Publications
Cat. No.: HY-148748
CAS No.: 1110767-45-7
Purity:  99.62%
Target:  

JAK STAT p38 MAPK

Research Areas:  

Cardiovascular Disease

Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .
loading...
    loading...
View All Sizes
3
Sennoside B
Sennoside B
0 Images
3 Cited Publications
Cat. No.: HY-N0366
CAS No.: 128-57-4
Category:  

Quinones Anthraquinones 500 - Internal Server Error | MedChemExpress

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.